公开(公告)号：US20210052642A1

公开(公告)日：2021-02-25

申请号：US16768930

申请日：2018-12-03

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services

发明人： Gal Cafri ,  Steven A. Rosenberg

IPC分类号： A61K35/15 ,  C12N5/0784 ,  C07K14/725

摘要： Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.

公开(公告)号：US20210046112A1

公开(公告)日：2021-02-18

申请号：US16943400

申请日：2020-07-30

申请人： National University of Singapore

发明人： Dario Campana ,  Takahiro Kamiya

IPC分类号： A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K35/15 ,  C07K16/28

摘要： The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

公开(公告)号：US20210038702A1

公开(公告)日：2021-02-11

申请号：US16936396

申请日：2020-07-22

申请人： MILTENYI BIOTEC B.V. & CO. KG

发明人： Jolanda DE VRIES ,  Carl FIGDOR ,  Ghaith BAKDASH

IPC分类号： A61K39/00 ,  C12N5/0784 ,  A61K35/15

摘要： The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c (BDCA-1)+/CD19− dendritic cells, wherein CD1c(BDCA-1)+/CD19− dendritic cells are depleted for CD1c (BDCA-1)+/CD19−/CD14+ cells.

公开(公告)号：US20210038643A1

公开(公告)日：2021-02-11

申请号：US16997738

申请日：2020-08-19

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Irving L. Weissman ,  Mingye Feng ,  Jens-Peter Volkmer

IPC分类号： A61K35/15 ,  A61K31/4745 ,  A61K31/713 ,  A61K39/39 ,  A61K31/519 ,  A61K39/395 ,  A61K45/06 ,  C12N5/0786

摘要： Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD4 7 blockade.

公开(公告)号：US10894061B2

公开(公告)日：2021-01-19

申请号：US15747902

申请日：2016-08-05

申请人： Regents of the University of Minnesota ,  St. Jude Children's Research Hospital, Inc. ,  Albert-Ludwig Universität Freiburg ,  The University of North Carolina at Chapel Hill

发明人： Bruce R. Blazar ,  Brent Koehn ,  Peter J. Murray ,  Jenny P. Y. Ting ,  Robert Zeiser ,  Jeff S. Miller

IPC分类号： A01N63/00 ,  A61K48/00 ,  A61K35/15 ,  C12N5/0787 ,  C12N5/078 ,  A61P37/06 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0786 ,  A61K35/12

摘要： In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

公开(公告)号：US20210002365A1

公开(公告)日：2021-01-07

申请号：US16969707

申请日：2019-02-14

申请人： YALE UNIVERSITY

发明人： Andrew Wang ,  Wenjun Liu ,  Aaron Ring

IPC分类号： C07K16/28 ,  A61K35/15 ,  A61K38/16

摘要： The present invention provides compositions and methods for reducing inflammation. In one aspect, the present invention provides a protein inhibitor comprising an ectodomain of at least one TREM or TREML protein. The invention also relates to inhibiting the interaction between a TREM or TREML protein and mitochondria released or derived from necroptotic cells; or between a TREM or TREML protein and cardiolipin.

公开(公告)号：US10821164B2

公开(公告)日：2020-11-03

申请号：US15738209

申请日：2016-06-06

申请人： SAINT LOUIS UNIVERSITY ,  EPIVAX, INC.

发明人： Daniel Hoft ,  Chris Eickhoff ,  Annie De Groot

IPC分类号： A61K39/00 ,  A61K38/00 ,  A61K39/005 ,  C12N9/00 ,  C12N9/24 ,  A61K35/15

摘要： The present disclosure relates to vaccine formulations and their use in treating and preventing Chagas Disease.

公开(公告)号：US20200330513A1

公开(公告)日：2020-10-22

申请号：US16695170

申请日：2019-11-25

申请人： Hector Manuel Zepeda Lopez

发明人： Hector Manuel Zepeda Lopez

IPC分类号： A61K35/15 ,  A61K38/10 ,  A61K38/17

摘要： Compositions, methods of use, and pharmaceutical preparations useful for modulation of immune responses are disclosed herein. In one embodiment a composition is extracted from immune organs or leukocytes derived from members of the chondrichthyes family through dialysis. Said immune modulator is useful for treatment of conditions requiring stimulations or regulation of immunity. In one embodiment, said immunomodulator controls T cell activation by modulation of cytokine production.

公开(公告)号：US10793599B2

公开(公告)日：2020-10-06

申请号：US15762480

申请日：2016-10-06

申请人： OncoTherapy Science, Inc.

发明人： Sachiko Yamashita ,  Tetsuro Hikichi

IPC分类号： C07K7/06 ,  A61K35/15 ,  A61K39/00 ,  A61K35/17 ,  C12N1/00 ,  C12N15/09 ,  C07K16/28 ,  A61K48/00 ,  C07K16/18 ,  C12N5/0783 ,  G01N33/50

摘要： The present invention provides MPHOSPH1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US10772911B2

公开(公告)日：2020-09-15

申请号：US15128660

申请日：2015-03-24

申请人： Advanced ReGen Medical Technologies, LLC

发明人： Steven John Greco ,  Vincent C. Giampapa

IPC分类号： A61K35/12 ,  A61K45/06 ,  A61K38/18 ,  A61K38/19 ,  A61K38/22 ,  A61K31/7105 ,  A61K35/15

摘要： A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.